The independent source for health policy research, polling, and news.
KFF’s policy research provides facts and analysis on a wide range of policy issues and public programs.
KFF designs, conducts and analyzes original public opinion and survey research on Americans’ attitudes, knowledge, and experiences with the health care system to help amplify the public’s voice in major national debates.
KFF Health News is a national newsroom that produces in-depth journalism about health issues and is one of the organization’s core operating programs.
The Abortion in the United States Dashboard is an ongoing research project tracking state abortion policies and litigation following the overturning of Roe v. Wade. It features a continuously-updated map tracking the status of abortion bans across the United States, as well as briefs on topics such as medication abortion, insurance coverage, ballot measures, legal developments, and racial and ethnic disparities. It also offers a jumping off point to the latest national and state-specific abortion policies and statistics. Visit the Dashboard →
Despite for calls from Republican leaders and anti-abortion organizations for the FDA to act quickly, the Louisiana district court has given the FDA until October 7, 2026, one month before the midterms, to file a report with the status of its review and any updated timeframe for completion. In the meantime, clinicians may continue to mail mifepristone to pregnant patients seeking abortions regardless of where they live.
False claims about the safety of mifepristone are driving legislative and investigative action in Congress, even as major medical organizations and decades of clinical evidence support the drug’s safety.
This policy tracker documents exceptions in each state’s most restrictive gestational limit or total ban.
Last updated on March 24, 2026 Since the Supreme Court’s Dobbs decision, overturning Roe v. Wade, voters in 17 states have weighed in on ballot measures regarding abortion-- some more than once. In November 2026, voters in Missouri, Nevada, and Virginia will weigh in on abortion measures that could change the legal status of abortion in their state. In addition, measures in Idaho and Nebraska are in the process of collecting signatures. In 2024, 10 states voted on abortion measures that sought to affirm that the state constitution protects the right to abortion. Nebraska voted on two measures: one…
This issue brief reviews the abortion-related initiatives currently slated to be on the ballot in November 2026 and examines how these measures may impact abortion access in the state.
Explore an overview of the Mexico City Policy and the Promoting Human Flourishing in Foreign Assistance (PHFFA) Policy
A new study found the FDA’s abortion pill decisions followed scientific evidence, as misleading claims about the drug’s safety continue to shape public understanding. And Google removed some health AI summaries after a Guardian investigation reported that AI-generated summaries contained false and potentially dangerous health information.
This analysis assesses the potential reach of the latest expansion of the Mexico City Policy, which is now part of the Promoting Human Flourishing in Foreign Assistance (PHFFA) Policy.
On Friday, January 23, 2026, the Trump administration released the latest expansion of the Mexico City Policy (MCP). The controversial policy, which had restricted foreign non-governmental organizations (NGOs) from performing or promoting abortion as a method of family planning as a condition of receiving most U.S. global health aid, has been broadened significantly to include more organizations (not just foreign NGOs) and most U.S. foreign aid. Also, the policy now prohibits activities related to diversity, equity, and inclusion (DEI) as well as support for gender-affirming care and services, and legal protections based on gender identity (among other activities). This move marked the most significant expansion of the MCP in more than 40 years — extending its reach far beyond the policy’s expansion during Trump’s first…
By suggesting mifepristone poses a danger to women who use it, anti-abortion senators are likely to create more confusion that could further erode the public's confidence in the abortion pill despite its decades-long safety record.
© 2026 KFF